Get a preview into the topics being discussed in the following sessions from the speakers who will be presenting:
Parallel Session 1:
Systemic Autoimmune Diseases
Monday 27 November 2017
|Gabriela Medina, Mexico|
|Metabolic syndrome, autoimmunity and autoimmune rheumatic diseases|
Metabolic syndrome (MetS) has increased in the last years throughout the world. Its prevalence is high among autoimmune rheumatic disease patients, leading to cardiovascular disease and consequently to death.
Mechanisms of interaction among MetS, autoimmunity and autoimmune rheumatic disease will be discussed, as well as preventive strategies.
Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ.Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10: 214-7.
Parallel Session 4: Systemic Lupus Erythematosus
Tuesday 28 November 2017
|Jose A Gómez-Puerta, Colombia|
|Urinary biomarkers in SLE|
The knowledge of biomarkers is crucial for practicioners in charge of patiens with autoimmune diseases, including SLE.
Interest on the study of biomarkers in lupus is increasing during last years.
Our aim is to discuss the main urinary biomarkers related with lupus nephritis and to understand their clinical relevance and correlations with different classes of lupus nephritis on kidney biopsies.
Plenary Session 6: Advances in Autoimmune Disease Therapy
Wednesday 29 November 2017
|Simone Appenzeller, Brazil||Role of antibodies and cytokines in CNS manifestations in SLE|
NP SLE is frequently observed and is a challange in clinical practice.
In this session, the role of antibodies and cytokines in NP SLE will be discussed.
Main mimickers of NP SLE will be presented.